MIM
TTPH

MetLife Investment Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

MetLife Investment Management’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-967
Closed -$122K – 2230
2017
Q4 		$122K Buy
+967
New +$124K ﹤0.01% 2168

Other funds holding TTPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

MetLife Investment Management's TTPH Position: Q1 2018 in Review

MetLife Investment Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2018, closing a stake of 967 shares — an estimated $122K sold.

MetLife Investment Management first reported a position in TTPH in Q4 2017 and held it in 1 quarter. The position peaked at $122K in Q4 2017. 94 funds tracked by Wall St. Rank hold TTPH as of Q1 2018.

  • MetLife Investment Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • MetLife Investment Management sold 967 Tetraphase Pharmaceuticals, Inc. shares in Q1 2018, an estimated $122K.
  • MetLife Investment Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • MetLife Investment Management's Tetraphase Pharmaceuticals, Inc. position peaked at $122K in Q4 2017.
  • 94 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2018.

Based on MetLife Investment Management's 13F filing for Q1 2018, filed 15 May 2018.